Dear NCCN Guidelines Panel for Small Cell Lung Cancer,

Request:
- Please consider Tecentriq® (atezolizumab) plus carboplatin and etoposide for the first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC) for inclusion into the guideline based on the results of the double-blind, placebo-controlled, Phase 3 IMpower133 trial published in the New England Journal of Medicine.
  - Patients enrolled in IMpower133 were randomized 1:1 to receive induction therapy with four cycles of carboplatin plus etoposide plus Tecentriq or placebo, followed by maintenance therapy with Tecentriq or placebo until intolerable toxicity, progressive disease or loss of clinical benefit.

Rationale:
- At a median follow-up of 13.9 months, Tecentriq plus carboplatin plus etoposide met both co-primary endpoints of improvement in overall survival and investigator-assessed progression-free survival compared to carboplatin plus etoposide for the first-line treatment of patients with ES-SCLC.
- The safety profile of Tecentriq plus carboplatin and etoposide was consistent with the individual medicines with no new signals observed.

FDA Clearance:
- Tecentriq plus carboplatin and etoposide is not FDA-approved for the treatment of patients with ES-SCLC. Please refer to the product prescribing information for the full FDA-approved indications and safety information, available at: https://www.gene.com/medical-professionals/medicines/tecentriq.

Any references supplied to you are protected under U.S. Copyright Law (Title 17, U.S. Code). No further reproduction is permitted.

Thank you for your consideration and I hope this information is helpful to you. If you have any questions, please contact us at the phone number and email provided above.

Respectfully submitted,
Jordana Wollmann, PharmD

References